Thank you, Madam Chairperson.
I want to try to zero in on what specifically the government is proposing with respect to this new approach around post-market surveillance, because I don't get those specifics from the paper, other than some talk about a life cycle approach.
I'm wondering what mechanism is in place or is being contemplated that will provide independent assessment of a drug, or any product, once it is on the market. Or is it all industry based? Is there any proposal for an independent post-market surveillance body?